HELLERUP, Denmark, April 6, 2021 /PRNewswire/ — UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe (LINK). With no serious adverse effects reported, the study showed a strong safety profile of inhaled and intranasal niclosamide which was the primary endpoint for the trial.
The promising safety and pharmacokinetic results for inhaled and intranasal niclosamide have opened the doors for further investigation, and will now be tested as a potential treatment (UNI91104) and prophylaxis (UNI91103) for COVID-19. Niclosamide was shown by Institut Pasteur to have a 40-fold better potency than remdesivir against SARS-CoV-2.
Local administration of niclosamide prompts new options for the treatment of COVID-19